Overview

Multicenter Study Evaluating 12 Versus 24 Weeks Therapy With Peginterferon and Ribavirin for Hepatitis C Virus (HCV) Genotype 2 or 3

Status:
Completed

Trial end date:
2006-10-01

Target enrollment:

Participant gender:

Summary

The primary objective of the study is to demonstrate that the efficacy of peginterferon alfa-2a 40KD combination therapy with ribavirin in interferon naïve patients with chronic hepatitis C virus infection genotype 2 or 3 given for 12 weeks is non-inferior to 24 weeks.

Phase:

Phase 4

Details

Lead Sponsor:

NORDynamIC Study Group

Treatments:

Interferon-alpha
Peginterferon alfa-2a
Ribavirin